Melanocortin 4 receptor mutation in obesity

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

HTML

Figures (1-1)

Tables (1-2)

Sum=13

Dec 20, 2024 (publication date) through Oct 31, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Experimental Medicine

ISSN

2220-315x

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Exp Med. Dec 20, 2024; 14(4): 99239
Published online Dec 20, 2024. doi: 10.5493/wjem.v14.i4.99239

Table 2 Drugs for use in genetic forms of obesity

Drug	Analogue
Setmelanotide	Analogue of α-melanocyte melanocyte-stimulating hormone
Metreleptin	Human leptin analogue
Liraglutide	Glucagon-like peptide-1 analogue
Semaglutide	Long-acting glucagon-like peptide-1 analogue
Others

Citation: Sridhar GR, Gumpeny L. Melanocortin 4 receptor mutation in obesity. World J Exp Med 2024; 14(4): 99239
URL: https://www.wjgnet.com/2220-315x/full/v14/i4/99239.htm
DOI: https://dx.doi.org/10.5493/wjem.v14.i4.99239